Navigation Links
Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C

rd of care alone, which could translate into improved clinical outcomes with longer treatment periods. In addition, the level of antiviral activity from 500mg to 1500mg provides flexibility in selecting doses for future clinical studies."

R7128 Phase 1 Combination Study Overview

The Phase 1 combination clinical trial was a multiple center, observer- blinded, randomized and placebo-controlled study that was conducted in 50 treatment-naive patients chronically infected with HCV genotype 1. The primary objective was to assess the safety, tolerability and pharmacokinetics of R7128 in combination with Pegasys plus Copegus. The secondary objective was to evaluate the change in HCV RNA after 4 weeks of treatment.

The study investigated two oral dose levels of R7128, 500mg and 1500mg, each administered twice-daily (BID) with once-weekly injections of Pegasys plus Copegus. Each cohort of 25 patients was comprised of 20 patients receiving active R7128 and 5 patients receiving placebo with Pegasys plus Copegus (standard of care). The initial evaluation period reported is 4 weeks.

Preliminary Antiviral Activity Summary

Combined Placebo + R7128 500mg + R7128 1500mg +

Pegasys plus Pegasys plus Pegasys plus

Copegus Copegus Copegus

(Standard of Care) (n=20) (n=20)


Mean Decrease in

HCV RNA (log10 IU/mL)

at 4 Weeks -2.95 -3.82 -5.12

Percentage of Patients

with Undetectable

HCV RNA (<15 IU/mL)

at 4 Weeks (RVR) 10% 30% 85%

Potent antiviral activity was demonstrated following 4 weeks of treatment with R7128 1500mg BID with Pegasys plus Copegus, in which patients achieved a mean 5.12 log10 IU/mL decrease in HCV

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
2. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
3. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
4. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
5. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
(Date:7/30/2014)... July 30, 2014 /PRNewswire-iReach/ -- This is a ... Chinese Heparin sodium (CAS 9041-08-1) & calcium (CAS ... information of Heparin sodium (CAS 9041-08-1) & calcium ... technology. The report then explores global and China,s ... calcium (CAS 37270-89-6) listing their product specification, capacity, ...
(Date:7/30/2014)... -- Hospira, Inc. (NYSE: HSP ), the ... technologies, today reported results for the second quarter ... quarter were $1.1 billion and adjusted* diluted earnings ... items as described later in this press release ... Accepted Accounting Principles (GAAP) basis, second-quarter 2014 diluted ...
(Date:7/30/2014)... , July 30, 2014   Medical Equipment Solutions, ... been awarded a Department of Defense (US Army) contract ... supply a mobile MRI diagnostic machine and technical support ... (WOSB) through the Small Business Administration (SBA), Medical Equipment ... field with the latest medical diagnostic equipment. The SBA ...
Breaking Medicine Technology:Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30Hospira Reports Second-Quarter 2014 Results 31Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2
... brand drug "copay coupon" promotions, which lure insured consumers ... by $2.1 billion in Florida over the next decade ... new research from Visante and released by the ... these promotions by state and local government workers alone ...
... PharmAthene, Inc. (NYSE Amex: PIP ) announced today ... agent bioscavenger programs will be presented at the 2011 Chemical ... held in Las Vegas, NV, November 14-18, 2011. ... biodefense industry meetings and it is an honor to present ...
Cached Medicine Technology:Brand Drug 'Copay Coupons' Undermine Generics, Raise Health Costs by $2.1 Billion in Florida 2PharmAthene to Present at the 2011 Chemical and Biological Defense Science and Technology Conference 2PharmAthene to Present at the 2011 Chemical and Biological Defense Science and Technology Conference 3
(Date:7/30/2014)... (PRWEB) July 30, 2014 In today’s world, ... difficult to get. Snoring and sleep apnea (a medical problem ... people and their bed partners of the rest they need ... of the population snores and 20 million people in the ... have been diagnosed and treated; and of those treated, many ...
(Date:7/30/2014)... 2014 The Independent Woman , a ... 6 free financial workshops in the Dallas area, August ... was crafted with significant input and guidance from Kim Kiyosaki, ... like more out of life. More time, more money, and ... is the key to these goals. “Money is no longer ...
(Date:7/30/2014)..., a recognized authority on law, update ... the FDA on snacks . , Dancing Star ... recalled because they contain organic Carob Powder ... Salmonella can cause serious, fatal infections in people with ... abdominal pain, vomiting, nausea, diarrhea, or fever. In rare ...
(Date:7/30/2014)... An interesting fact about motorcyclists was recently ... congregate, . The number and ratio of ... BikerKiss indicate that women motorcycle riders have been in ... Members on BikerKiss are mostly single bikers ... European countries who are there looking for friendship or ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Neil Haley, the ... Vi Millionaire GJ Reynolds to find out about what is ... create the best brand. , Reynolds is an original founding ... Star Ambassador, Vi Millionaire, and CEO of Simply G Media. ... Warrior Within You!" and holds the distinction of completing the ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:The Independent Woman Will Offer Financial Workshops Developed by Women for Women in the Dallas Area 2Health News:Various Snacks by Dancing Star Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Various Snacks by Dancing Star Recalled: AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Single Women Motorcycle Riders In Rapid Increase 2Health News:Entrepreneur and Vi Millioniare GJ Reynolds Discusses How to Improve Your Brand on the Simply G Radio Show, a Division of the Simply G Media Network 2
... occurs in sperm could be the key to a new ... an ion channel protein that controls the flow of calcium ... swim, so a drug designed to block the channel would ... in this week's Nature by Dr Arnold Clapham, from the ...
... cell disease is an inherited blood disorder that affects ... red blood cells that contain an abnormal type of ... have difficulty passing through small blood vessels. When sickle-shaped ... is often pain severe enough to require hospital admission. ...
... intestine could hold the key to permanent weight loss. ... is produced in the small intestine in response to ... development of better treatments for eating disorders and obesity. ... and profoundly different from those of traditional appetite suppressants. ...
... that tend to be slightly elevated but still considered ... for suffering from heart disease. Blood pressure readings are ... first number in a blood pressure measurement, represents the ... the diastolic value, represents the pressure when the heart ...
... be mindful of the possible interaction between oral ... Centers for Disease Control and Prevention (CDC) to ... and anti-infective medications, such as Cipro, doxycycline, and ... have been exposed to anthrax spores.// Many antibiotics ...
... significant breakthrough, a team of scientists have successfully transplanted ... diseased one, bringing light to the people who nearly ... about stem cells, in all 33 patients who suffered ... drug and auto-immune diseases causing damage to the part ...
Cached Medicine News:
... mirrors angled at 76°, 66° and 60°. ... well as central and peripheral fundus viewing and ... angled and spaced 120° apart to eliminate "gaps" ... of the lens also provides direct observation of ...
The Mid Field 30° lens has a bi-concave design to provide a wider field of view with a 30 degree offset image....
... 30° Prism are designed for ... recommended for tractional retinal detachments ... retinal detachment. They can be ... other midperipheral laser applications. Direct ...
... The Chalam 15° Prism ... pathologies and are recommended for ... etc.) and Rhegmatogenus retinal detachment. ... panretinal photocoagulation and other midperipheral ...
Medicine Products: